Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmine Valenza

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancerCarmine Valenza, Giuseppe Curigliano
Current Opinion in Oncology|September 9, 2022
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancerCarmine Valenza, Dario Trapani, Giuseppe Curigliano
Current Opinion in Oncology|August 25, 2023
Immunotherapy for inflammatory breast cancer: current evidences and future perspectivesCarmine Valenza, Dario Trapani, Giuseppe Curigliano
Expert Opinion on Investigational Drugs|June 28, 2022
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?Federica Giugliano, Carmine Valenza, Paolo Tarantino, et al.
Current Opinion in Oncology|September 9, 2024
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatmentsCarmine Valenza, Renato Maria Marsicano, Dario Trapani, et al.
Cancers|February 25, 2023
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future ChallengesLorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, et al.
Cancer Treatment and Research|January 4, 2024
New Concepts in Cardio-OncologyPaola Zagami, Eleonora Nicolò, Chiara Corti, et al.
Expert Opinion on Investigational Drugs|November 22, 2022
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022Beatrice Taurelli Salimbeni, Carla Corvaja, Carmine Valenza, et al.
Molecular Cancer Therapeutics|February 16, 2024
Biomarkers for Antibody-Drug Conjugates in Solid TumorsJalissa Katrini, Laura Boldrini, Celeste Santoro, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
Advancing Antibody-Drug Conjugates: Current Perspectives and Future DirectionsJulian David Etessami, Carmine Valenza, Anthony W Tolcher, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancerCarmine Valenza, Giuseppe Curigliano
Current Opinion in Oncology|September 9, 2022
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancerCarmine Valenza, Dario Trapani, Giuseppe Curigliano
Current Opinion in Oncology|August 25, 2023
Immunotherapy for inflammatory breast cancer: current evidences and future perspectivesCarmine Valenza, Dario Trapani, Giuseppe Curigliano
Expert Opinion on Investigational Drugs|June 28, 2022
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?Federica Giugliano, Carmine Valenza, Paolo Tarantino, et al.
Current Opinion in Oncology|September 9, 2024
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatmentsCarmine Valenza, Renato Maria Marsicano, Dario Trapani, et al.
Cancers|February 25, 2023
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future ChallengesLorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, et al.
Cancer Treatment and Research|January 4, 2024
New Concepts in Cardio-OncologyPaola Zagami, Eleonora Nicolò, Chiara Corti, et al.
Expert Opinion on Investigational Drugs|November 22, 2022
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022Beatrice Taurelli Salimbeni, Carla Corvaja, Carmine Valenza, et al.
Molecular Cancer Therapeutics|February 16, 2024
Biomarkers for Antibody-Drug Conjugates in Solid TumorsJalissa Katrini, Laura Boldrini, Celeste Santoro, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 14, 2026
Advancing Antibody-Drug Conjugates: Current Perspectives and Future DirectionsJulian David Etessami, Carmine Valenza, Anthony W Tolcher, et al.
Pageof 6